IN8bio (INAB) said Tuesday that new data from the ongoing early-stage study of INB-100 showed that 100% of acute myeloid leukemia patients in the original and expansion groups through Jan. 17 remained in complete remission.
The company said INB-100, which is designed to help patients with complex leukemias, such as AML, also showed improved survival compared with standard treatment.
The investigational therapy also "appears to be well-tolerated" and has no significant effect on patient quality of life, the company said.
Shares of IN8bio were up 71% in recent premarket activity on Tuesday.
Price: 0.4797, Change: +0.21, Percent Change: +77.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。